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Background: Lamins A and C, two major structural components of the nuclear lamina that determine nuclear
shape and size, are phosphoproteins. Phosphorylation of lamin A/C is cell cycle-dependent and is involved in
regulating the assembly–disassembly of lamin filaments during mitosis. We previously reported that P-STM, a
phosphoepitope-specific antibody raised against the autophosphorylation site of p21-activated kinase 2, recognizes
a number of phosphoproteins, including lamins A and C, in mitotic HeLa cells.
Results: Here, using recombinant proteins and synthetic phosphopeptides containing potential lamin A/C
phosphorylation sites in conjunction with in vitro phosphorylation assays, we determined the lamin A/C
phosphoepitope(s) recognized by P-STM. We found that phosphorylation of Thr-19 is required for generating the
P-STM phosphoepitope in lamin A/C and showed that it could be created in vitro by p34cdc2/cyclin B kinase
(CDK1)-catalyzed phosphorylation of lamin A/C immunoprecipitated from unsynchronized HeLa S3 cells. To further
explore changes in lamin A/C phosphorylation in living cells, we precisely quantified the phosphorylation levels of
Thr-19 and other sites in lamin A/C isolated from HeLa S3 cells at interphase and mitosis using the SILAC method
and liquid chromatography-tandem mass spectrometry. The results showed that the levels of phosphorylated
Thr-19, Ser-22 and Ser-392 in both lamins A and C, and Ser-636 in lamin A only, increased ~2- to 6-fold in mitotic
HeLa S3 cells.
Conclusions: Collectively, our results demonstrate that P-STM is a useful tool for detecting Thr-19-phosphorylated
lamin A/C in cells and reveal quantitative changes in the phosphorylation status of major lamin A/C
phosphorylation sites during mitosis.
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The nuclear envelope consists of inner and outer nuclear
membranes, nuclear pore complexes, and the underlying
nuclear lamina. The nuclear lamina connects with both
integral membrane proteins of the inner nuclear mem-
brane and chromatin [1]. Nuclear lamins are intermedi-
ate filament proteins that are the major components of
the nuclear lamina. Lamins are type V intermediate fila-
ment proteins consisting of a central coiled-coil region* Correspondence: yusong@mail.cgu.edu.tw
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reproduction in any medium, provided the orand globular N- and C-terminal domains. They are classi-
fied into two subgroups: A-type and B-type. A-type
lamins, including lamin A (74 kDa) and lamin C (65 kDa),
are alternatively spliced products of a single gene locus,
with lamin A having an extra 98 amino acid residues at its
C-terminus that are not present in lamin C [1,2]. During
the mitotic phase of every cell cycle in eukaryotes, the
structure of the nuclear envelope undergoes a dramatic as-
sembly and disassembly process. The nuclear lamina de-
polymerizes as a result of mitosis-specific phosphorylation
of the nuclear lamins at specific sites [3,4]. Several kinases,
including p34cdc2/cyclin B (CDK1), CDK5, protein kinase
C (PKC) and Akt/protein kinase B (PKB), are reported to
phosphorylate lamin A/C on different sites during mito-
sis or under certain physiological/pathological conditionstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ation sites have been determined [5]. Mutation of two
lamin A phosphorylation sites, Ser-22 (in QASSTP
LS22PTRIT) and Ser-392 (in RLRLSPS392PTSQR), has
been reported to prevent nuclear lamina disassembly in
mitotic cells [3].
Phosphoepitope-specific antibodies that selectively re-
cognize phosphorylated, but not non-phosphorylated,
forms of a variety of protein kinases or their substrates are
valuable tools for measuring kinase activity and substrate
phosphorylation during numerous cellular events [10-13].
Many of these antibodies are generated in animals using a
specific phosphopeptide as the antigen. Because the phos-
phate group is a common structure present in every phos-
phopeptide antigen, an anti-phosphopeptide antibody
raised against a specific phosphopeptide may display a
broader immunoreactivity, interacting with structurally
similar phosphorylated motifs [14-17].
PAK2, a member of the p21-activated kinase (PAK)
family, participates in regulating diverse cell functions,
including cell morphogenesis, motility, survival, apop-
tosis, mitosis, and angiogenesis [18,19]. Previously, we
identified Thr-402 as the autophosphorylation regulatory
site of the catalytic fragment of PAK2 [20]. We subse-
quently generated a phosphoepitope-specific antibody,
P-STM, using the synthetic phospho-STM-11-C peptide,
S398KRSTp402MVGTPYC408, which encompasses the se-
quence of the regulatory autophosphorylation site of
PAK2, as an antigen. This antibody recognizes the
autophosphorylated/activated, but not the unphospho-
rylated/inactive, form of PAK2 [20]. Interestingly, we
found that P-STM also reacted with a number of mitotic
phosphoproteins in human A431 and HeLa cells [21] that
are different from those detected by MPM-2, a monoclo-
nal antibody raised against total lysates of mitotic HeLa
cells that recognizes more than 40 mitotic phosphopro-
teins [22,23]. Using two-dimensional gel electrophoresis
and matrix-assisted laser desorption/ionization-time of
flight (MALDI-TOF) mass spectrometry, we further iden-
tified lamins A and C as two of the mitotic cell-specific
phosphoproteins recognized by P-STM [21]. However, the
exact lamin A/C phosphoepitope(s) recognized by P-STM,
the kinase responsible for generating the phosphoepitope
(s), as well as quantitative changes in the phosphoepitope
(s) between interphase and mitosis, remained elusive.
The aims of this study were to identify the lamin A/C
phosphoepitope(s) recognized by P-STM in mitosis and
quantify differential phosphorylation of lamin A/C phos-
phorylation sites at interphase and mitosis using liquid
chromatography-tandem mass spectrometry (LC-MS/
MS) coupled with the SILAC (stable isotope labeling by
amino acids in cell culture) approach. We found that
CDK1-catalyzed phosphorylation of lamin A/C at
Thr-19 created a P-STM-recognizable phosphoepitope.SILAC-based quantitative mass spectrometric analyses of
lamin A/C isolated from HeLa S3 cells at interphase and
mitosis further revealed 2.3- to 5.6-fold increases in the
phosphorylation levels of Thr-19, Ser-22 and Ser-392 in
lamins A and C, and Ser-636 in lamin A only, in mitotic
compared with interphase HeLa S3 cells. Among the four
sites identified and quantified, Thr-19 and Ser-22
showed the most dramatic cell cycle-dependent changes
in phosphorylation.
Results
Phosphorylation of interphase lamin A/C by CDK1 Creates
a P-STM phosphoepitope
We have previously shown that lamins A and C are two of
the mitotic phosphoproteins recognized by the P-STM
antibody [21]. Because the CDK1 complex is known to
phosphorylate lamin A/C at multiple sites during mitosis
[3-6], we tested whether interphase lamin A/C can be
phosphorylated in vitro by CDK1 to create a P-STM
phosphoepitope. Lamins A and C were immunopre-
cipitated from total extracts of unsynchronized HeLa S3
cells and in vitro-phosphorylated by CDK1. The reaction
products, as well as total extracts of HeLa S3 cells, treated
without or with nocodazole (Noc), were then immu-
noblotted with anti-lamin A/C antibody or P-STM. Both
lamins A and C were efficiently immunoprecipitated and
detected with anti-lamin A/C antibody (Figure 1, left
panel). After in vitro CDK1-catalyzed phosphorylation of
immunoprecipitated lamin A/C, two major additional
P-STM-immunoreactive signals corresponding to phos-
phorylated lamins A and C emerged (Figure 1, right panel;
compare lanes 3 and 4), indicating that CDK1-mediated
phosphorylation of interphase lamins A and C generates
P-STM-recognizable phosphoepitope(s) in vitro.
In vitro phosphorylation of recombinant GST-Lamin A/C
by CDK1 creates a P-STM phosphoepitope
To identify the CDK1-dependent phosphorylation site(s)
on lamin A/C recognized by P-STM, we performed
in vitro phosphorylation assays using bacterially expressed,
recombinant GST-lamin A/C fusion proteins as substrates
for CDK1. These fusion proteins cover different domains
(N, amino acids [aa] 1–375 covering Coil 1A and 1B do-
mains; N1, aa 1–57 covering Coil 1A domain; N2, aa
68–375 covering Coil 1B domain; and C, aa 376–572 cov-
ering Coil 2 domain and the nuclear localization signal) of
lamin C (Figure 2A) containing known phosphorylation
sites for CDK1 (Thr-19, Ser-22, Ser-390, and Ser-392),
PKC (Ser-403 and Ser-404), or Akt/PKB (Ser-404). The
reaction products were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and subjected to protein staining, autoradiography, and
immunoblotting with P-STM (Figure 2B). Although radi-
ography revealed that the N-terminal region (aa 1–375)
Figure 1 CDK1-catalyzed phosphorylation of interphase lamins A and C enhances their P-STM immunoreactivity. Total extracts
(TE; 60 μg) from HeLa S3 cells treated for 14 h with DMSO (lane 1) or Noc (1 μg/mL; lane 2) were resolved by SDS-PAGE on 10% gels and
immunoblotted (IB) with P-STM antibody or anti-lamin A/C antibody. Lamins A and C were immunoprecipitated (IP) from total extracts of
unsynchronized cells (2 mg) and then in vitro-phosphorylated by incubating with CDK1 (lane 4) for 30 min; immunoprecipitates incubated
without CDK1 (lane 3) served as controls. IP products were resolved by SDS-PAGE on 10% gels and analyzed by immunoblotting as described.
Figure 2 Identification of CDK1-catalyzed phosphorylation site(s) on lamin A/C as P-STM phosphoepitope(s). (A) A schematic diagram of
full-length lamin C (aa 1–572) and different truncated forms (N, N1, N2, and C) of GST-lamin C. (B) The four purified GST-lamin C recombinant
proteins (1.5 μg) were in vitro-phosphorylated by CDK1 in the presence of [γ-32P]-ATP. Reaction products were resolved by SDS-PAGE on 10% gels
and visualized by Coomassie Blue staining (upper panel), followed by autoradiography (middle panel) or immunoblotting with P-STM antibody
(lower panel). (C) A schematic diagram of GST-lamin C-N1 mutants. Mutants were generated by site-directed mutagenesis to replace Thr-19,
Ser-22, or Thr-19/Ser-22 with Ala. (D) The four purified GST-lamin C-N1 fusion proteins (1.5 μg) were phosphorylated by CDK1 and processed as
described above.
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Figure 3 Mapping the P-STM phosphoepitope on lamin A/C
using synthetic phosphopeptides. (A) Sequences and properties
of the synthetic peptides used in this study. (B) GST-lamin C-N1
protein (0.5–2 μg), phosphorylated without or with CDK1, and
synthetic peptides (10 μg) were subjected to dot-blot analysis with
the P-STM antibody. (C) Lamins A and C were immunoprecipitated
from total extracts (1 mg) of Noc-treated HeLa S3 cells and resolved
by SDS-PAGE on 10% gels. Upper panel: In competition assays, the IP
products were analyzed by immunoblotting with P-STM antibody in
the presence of the indicated peptide (50 μg/mL). Lower panel:
Immunoblot analysis of the same IP products using an anti-lamin
A/C antibody (loading control).
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the C-terminal region (aa 376–572), were strongly phos-
phorylated by CDK1, a P-STM phosphoepitope was cre-
ated by CDK1 only in the intact N-terminal and N1
regions. These results indicate that the CDK1-dependent
P-STM phosphoepitope is located within the N1 region
(aa 1–57) of lamin A/C.
CDK1-mediated Thr-19 phosphorylation of lamin A/C
produces a P-STM phosphoepitope
In the N1 region (aa 1–57) of lamin A/C, two residues
(Thr-19 and Ser-22) are known to be phosphorylated by
CDK1 during mitosis [4]. Taken together with the data
shown above, this suggests that phosphorylation of Thr-
19 and/or Ser-22 by CDK1 may create the P-STM
phosphoepitope. To test this hypothesis, we replaced
Thr-19 and/or Ser-22 in the N1 region of lamin A/C with
Ala by site-directed mutagenesis, and expressed and puri-
fied these mutated GST-fusion proteins (N1-T19A,
N1-S22A, and N1-T19A/S22A) (Figure 2C). These recom-
binant proteins were in vitro-phosphorylated by CDK1,
and the reaction products were analyzed as described
above. The results showed that mutation of Thr-19, but
not Ser-22, to Ala completely blocked formation of the
P-STM phosphoepitope, although all three mutated pro-
teins could still be phosphorylated by CDK1 (Figure 2D).
In addition, dot-blot analyses using synthetic phospho-
peptides A–D (Figure 3A), which mimic the tryptic diges-
tion products of phosphorylated lamin A/C containing aa
12–25, were further performed to confirm the P-STM
phosphoepitope. These dot-blot experiments clearly
showed that the P-STM antibody could detect both the
CDK1-phosphorylated GST–N1 fusion protein and the
authentic P-STM peptide antigen used to generate the
P-STM antibody (Figure 3B). Under the assay conditions
used, we found that the P-STM antibody recognized pep-
tide B (SGAQASSTp19PLSPTR) and, to a lesser extent,
peptide A (SGAQASSTp19PLSp22PTR), but not peptides
C (SGAQASSTPLSp22PTR) or D (SGAQASST19PLS22P
TR) (Figure 3B). Moreover, the immunoreactivity of the
P-STM antibody toward lamins A and C immunopre-
cipitated from Noc-treated HeLa S3 cells was signifi-
cantly blocked by inclusion of peptide B and, to a lesser
extent, peptide A, but not peptide C or D, in immuno-
blot competition assays (Figure 3C). Taken together,
these results indicate that phosphorylation of Thr-19 in
lamin A/C by CDK1 during mitosis creates the P-STM
phosphoepitope.
LC-MS/MS-based identification of phospho-Thr-19 and/or
-Ser-22-containing peptides derived from a GST–N1
fusion protein phosphorylated by CDK1 in vitro
We have shown that phosphorylation of Thr-19 in lamin
A/C by CDK1 can generate a P-STM phosphoepitopeand that the P-STM antibody can recognize both mono-
phosphorylated peptide B (SGAQASSTp19PLSPTR) and
dual-phosphorylated peptide A (SGAQASSTp19PLSp22
PTR). However, it is not clear whether the mono-
phosphopeptide (peptide B) or dual phosphopeptide
(peptide A) form produced by CDK1-catalyzed phos-
phorylation of lamin A/C is the major contributor to the
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this issue, we applied LC-MS/MS to directly detect pep-
tides A–D in tryptic digestion products of GST–N1 fusion
protein phosphorylated by CDK1 in vitro. First, equal
amounts of the four model synthetic peptides A–D
(6 pmol each) were mixed and applied to LC-MS/MS to
generate standard chromatograms and MS/MS spectra for
comparison. As shown in Figure 4A (upper panel), pep-
tides A, B and D coeluted almost together, followed imme-
diately by peptide C; the rank order of signal intensity of
these peptides was peptide D > peptide C > peptide B > >
peptide A. Subsequent MS/MS analysis of each target pep-
tide based on its known mass and MS/MS spectral assign-
ments unambiguously identified all four peptide standards
in one LC-MS/MS run (Figure 4A and Additional file 1:
Figure S1). Interestingly, although peptides B (SGAQA
SSTp19PLSPTR) and C (SGAQASSTPLSp22PTR) are
mono-phosphopeptide isomers with the same mass and
isoelectric point (Figure 3A), they could still be separated
and unambiguously identified under the LC-MS/MS con-
ditions used here.
We then used these assay conditions to analyze the
tryptic peptides derived from the GST–N1 fusion pro-
tein (6 pmol) that had been phosphorylated by CDK1
in vitro. All four peptide forms were clearly detected byFigure 4 LC-MS/MS analysis of synthetic phosphopeptides and trypti
by CDK1 in vitro. (A) A mixture of the four synthetic peptides (A–D, 6 pmol
micrOTOFq. Upper panel: Base peak chromatogram (BPC) and extracted ion ch
four peptides used to assign amino acid sequences. (B) The tryptic peptides d
phosphorylated by CDK1 in vitro were separated and detected by LC-MS/MS
peptides corresponding to peptide A-D are highlighted. Lower panel: MS/MSLC-MS/MS analysis (Figure 4B and Additional file 1:
Figure S2), and the patterns of MS/MS spectra for the
four peptides obtained from this in vitro-phosphorylated
sample were almost identical to those of synthetic pep-
tide standards (see lower panels of Figure 4 for compari-
son). Importantly, both mono-phosphopeptide C (SGA
QASSTPLSp22PTR) and di-phosphopeptide A (SGAQ
ASSTp19PLSp22PTR) forms were present in larger
amounts than the mono-phosphopeptide B (SGAQ
ASSTp19PLSPTR) form (Figure 4B, upper panel). Col-
lectively, these results indicate that CDK1 exhibits mul-
tiple phosphorylation modes towards the N-terminal
region of lamin A/C and suggest that dual phosphoryl-
ation of lamin A/C on Thr-19 and Ser-22 makes a major
contribution to the formation of the P-STM-immunore-
active site.
SILAC-based quantification of differences in levels of site-
specific lamin A and C phosphorylation between
interphase and mitosis
The SILAC method, used in conjunction with LC-MS
/MS, has been shown to be a powerful approach for ana-
lyzing quantitative changes in the proteome of viable
cells [24,25]. This approach has also been applied to dis-
sect changes in site-specific phosphorylation of targetc peptides derived from GST–N1 fusion protein phosphorylated
each) was separated and detected simultaneously by LC-MS/MS using
romatogram (EIC) of a single LC run. Lower panel: MS/MS spectra of the
erived from the GST–N1 fusion protein (0.2 μg, 6.25 pmol)
using micrOTOFq. Upper panel: BPC and EIC of a single LC run; tryptic
spectra of the four tryptic peptides used to assign amino acid sequences.
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To gain insight into the quantitative changes in the
phosphorylation status of lamin A and C phosphoryl-
ation sites during mitosis, we applied the SILAC method
and LC-MS/MS to quantify the levels of multiple phos-
phorylation sites of lamin A and C isolated from HeLa
S3 cells at interphase and mitosis. The workflow is
depicted in Figure 5A. Briefly, HeLa S3 cells were grown
in medium containing light or heavy amino acids for six
doubling times. In condition 1, ‘light’ and ‘heavy’ cells
were treated for 16 h with Noc (1 μg/mL) and DMSOFigure 5 SILAC-based quantification of tryptic peptides of lamins A a
mitosis. (A) Workflow of the SILAC experiment. LD and LN, light isotope-lab
isotope-labeled cells treated with DMSO and Noc, respectively. See text for
and visualized by Coomassie Blue staining. Arrows indicate the protein ban
(C) Representative mass spectra of selected pairs of non-phosphopeptides
panel) in the SILAC experiment. Data were taken from the first experiment,
the second experiment, condition 1.(vehicle control), respectively; treatments were reversed
in condition 2 (DMSO and Noc for light and heavy, re-
spectively). This experimental paradigm allowed us to
obtain interphase and mitosis populations from both
treatment combinations. Extracts from both sets of cells
were mixed at a 1:1 ratio and immunoprecipitated using
an anti-lamin A/C antibody. The immunoprecipitated
products were then separated by SDS-PAGE, followed
by Coomassie Blue staining. The protein staining pattern
is shown in Figure 5B. Gel bands corresponding to
lamins A and C were excised for in-gel tryptic digestion,nd C immunoprecipitated from HeLa S3 cells at interphase and
eled cells treated with DMSO and Noc, respectively; HD and HN, heavy
details. (B) The IP products were separated by SDS-PAGE on 10% gels
ds corresponding to lamins A and C that were excised for MS analysis.
and phosphopeptides from lamin A (upper panel) and lamin C (lower
condition 1, except for SGAQASSTPLSPTR of lamin C, which was from
Table 1 SILAC-based quantification of tryptic
phosphopeptides and their corresponding non-
phosphopeptides derived from immunoprecipitated
lamins A and C
Lamin A
Start End Peptide sequence Normalized Ratio (Noc/DMSO)
12 25 SGAQASSTPLSPTR 5.40
12 25 SGAQASSTPLSPTR 5.49
12 25 SGAQASSTPLSPTR 0.60
387 397 LRLSPSPTSQR 2.42
387 397 LRLSPSPTSQR 0.43
389 397 LSPSPTSQR 0.76
628 644 SVGGSGGGSFGDNLVTR 2.02
628 644 SVGGSGGGSFGDNLVTR 0.84
Lamin C
Start End Peptide sequence Normalized Ratio (Noc/DMSO)
12 25 SGAQASSTPLSPTR 5.49
12 25 SGAQASSTPLSPTR 3.47
12 25 SGAQASSTPLSPTR 0.57
387 397 LRLSPSPTSQR 2.27
387 397 LRLSPSPTSQR 0.47
389 397 LSPSPTSQR 0.70
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/MS analysis, followed by MS data processing and quan-
titative analysis using the peptide quantification pipeline
(see Methods for details).
Using this strategy, we identified and quantified 65 pep-
tides in isolated lamin A and 61 peptides in isolated lamin
C (Additional file 2: Table S1), achieving 64% sequence
coverage for lamin A and 66% sequence coverage for
lamin C (Additional file 1: Figure S3 and S4). Of these
peptides, 55 of 65 (84.6%) of those for lamin A and 47 of
61 (77%) of those for lamin C exhibited an average fold-
change (Noc-treated/DMSO control) between 0.8 and 1.2.
The mean and median of average fold-changes for all
quantified peptides were 1.23 and 1.07 for lamin A and
1.27 and 1.13 for lamin C, respectively (Additional file 2:
Table S1), indicating that DMSO-treated and Noc-treated
cell pools contained approximately equal amounts of
lamin A and C proteins, and that the levels of most
detected peptides from lamins A and C were not signifi-
cantly changed by Noc treatment. Most quantitation re-
sults were reproducible in a second biological replicate
of the experiment (Additional file 2: Table S1). From
Additional file 2: Table S1, however, it is clear that Noc




SQR397, S628VGGSGGGSp636FGDNLVTR644, and S628V
GGSGGGSFGDNLVTR644) from lamin A and six pep-
tides (S12GAQASSTp19PLSp22PTR25, S12GAQASSTPL
Sp22PTR25, S12GAQASSTPLSP- TR25, L387RLSp390P
Sp392PTSQR397, L387RLSp390PSPTSQR397, and L389SPS
PTSQR397) from lamin C in HeLa S3 cells. These results
are further summarized in Table 1.
This quantitative analysis revealed that in mitotic HeLa
S3 cells (i) mono-phosphorylation of S12GAQASST
PLSPTR25 at Ser-22 and di-phosphorylation of S12GA
QASSTPLSPTR25 at both Thr-19 and Ser-22 were the
most prominent phosphorylation events (3.5–5.5 fold in-
crease) on lamins A and C; (ii) di-phosphorylation of
L389SPSPTSQR397 at both Ser-390 and Ser-392 on lamins
A and C were increased 2.3–2.4 fold, in association with a
parallel 53–57% decrease in mono-phosphorylation of
L389SPSPTSQR397 at Ser-390; and (iii) phosphorylation of
S628VGGSGGGSFGDNLVTR644 at Ser-636 on lamin A
was augmented 2.0 fold (Table 1). Representative mass
spectra of selected non-phosphopeptide and phosphopep-
tide pairs from lamins A and C in this SILAC-based ex-
periment are presented in Figure 5C.
Discussion
In this study, we identified phospho-Thr-19 of lamin A/C
as the phosphoepitope recognized by P-STM, a polyclonal
antibody originally generated against the regulatoryautophosphorylation site of PAK2. This phosphoepitope
can be created in vitro by CDK1-catalyzed phosphoryl-
ation of recombinant GST-lamin C-N1 protein (Fig-
ure 2). Moreover, an LC-MS/MS analysis of this in vitro
phosphorylation product clearly indicated that Thr-19 and
Ser-22 are the two prominent sites phosphorylated by
CDK1 (Figure 4). Taken together with the demonstration
by SILAC-based quantitative MS analysis that the level of
Thr-19 phosphorylation on lamin A/C increased >5 fold
in mitotic HeLa S3 cells (Figure 5 and Table 1), these ob-
servations indicate that CDK1-mediated Thr-19 phos-
phorylation of lamin A/C is responsible for generating the
phosphoepitope recognized by P-STM in mitotic cells.
As noted above, the nuclear lamina depolymerizes as a
result of mitosis-specific phosphorylation of nuclear
lamins at specific sites [3,4]. The functional roles of some
phosphorylation sites of lamin A/C in cell-cycle progres-
sion or in certain physiological settings have been inves-
tigated. For example, mutation of Thr-19, Ser-22, or
Ser-392 (phosphorylation site of CDK1) to Ala on lamin A
significantly inhibits lamin A disassembly in mitotic cells,
whereas mutation of both Ser-403 and Ser-404 (phosphor-
ylation site of other kinases) to Ala inhibits the transport
of mutant lamin A to the nucleus [4]. The major phos-
phorylated sites of lamin A/C are located on both sides of
the α-helical central rod domain, and phosphorylation at
these sites is known to interfere with the formation of
lamin head-to-tail polymers from lamin dimers [27].
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CDK5, which induces the nuclear lamin A dispersion that
leads to CDK5-mediated neurotoxicity, has been observed
in neuronal cells challenged by neurotoxic stimuli (amyl-
oid-β and glutamate) [7]. This CDK5-mediated nuclear
lamin A dispersion and neurotoxicity is significantly di-
minished by introduction of phosphorylation-resistant
mutations (S22A, S392A) in lamins, highlighting CDK5-
mediated Ser-22/Ser-392 phosphorylation as a major
mechanism for the neuronal death elicited by neurotoxic
stimuli [7]. In addition, as first demonstrated by Cenni
et al. [28], lamin A N-terminal phosphorylation is associ-
ated with myoblast activation, and this phosphorylation is
significantly impaired in mature muscle fibers from pa-
tients with Emery-Dreifuss muscular dystrophy (EDMD).
These authors subsequently demonstrated that (i) Akt ac-
tivated by insulin phosphorylates lamin A/C at Ser-404 in
C2C12 mouse myoblasts, but this phosphorylation cannot
be detected in primary cells from an EDMD-2 patient; (ii)
Akt phosphorylation at Ser-404 targets the precursor
prelamin A for degradation; and (iii) Akt regulates tran-
scription of the gene encoding lamin A (LMNA) [8,9,29].
Moreover, specific phosphorylation of Ser-458 of A-type
lamins in LMNA-associated myopathy patients has been
reported, although the role of this phosphorylation re-
mains to be established [30].
To facilitate study of the site-specific alteration of phos-
phorylation levels on lamins during mitosis or in other
physiological settings, research laboratories and biotech-
nology companies have produced several phosphoepitope-
specific antibodies against specific phosphorylation sites of
lamins. For instance, Kuga developed monoclonal anti-
bodies against five specific phosphorylation sites (Thr-14,
Ser-17, Ser-385, Ser-387, and Ser-401) of lamin B2 and
used these antibodies to study dynamic changes at these
phospho-sites in lamin B2/B1 throughout the cell cycle
[31]. However, only a few phosphoepitope-specific anti-
bodies against lamin A/C, including those against
phospho-Ser-22, phospho-Ser-392, phospho-Ser-404 [8],
and phospho-Ser-458 [30], have been reported, although
the antibody raised against the phospho-Ser-17 of lamin
B2 should also be included since it recognizes the homolo-
gous residue (phospho-Ser-22) in lamin A/C [31]. Our
current study demonstrates that the P-STM antibody rep-
resents a useful tool for investigating the Thr-19 phos-
phorylation of lamin A/C in living cells.
LC-MS/MS analyses of the GST–N1 fusion protein
in vitro-phosphorylated by CDK1 revealed the presence of
phospho-Thr-19 and/or phospho-Ser-22 in two mono-
phosphopeptides (SGAQASSTPLSp22PTR and SGAQAS
STp19PLSPTR) and one di-phosphopeptide (SGAQASS-
Tp19PLSp22PTR)(Figure 4B). Using the same LC-MS/MS
conditions to analyze lamin A/C immunoprecipitated from
equal mixtures of interphase and mitotic HeLa S3 cellextracts, however, we only detected the phospho-Ser-22-
containing peptide, SGAQASSTPLSp22PTR, and the
phospho-Thr-19/phospho-Ser-22-containing peptide, SGA
QASSTp19PLSp22PTR; the phospho-Thr-19-containing
peptide, SGAQASSTp19PLSPTR, in the N-terminal region
of lamin A/C was not detected (Table 1 and Additional file
2: Table S1). This observation seems to indicate that, in mi-
totic HeLa S3 cells, mono- and dual-phosphorylation of
the peptide S12GAQASSTPLSPTR25 at Ser-22 and Thr-19/
Ser-22, respectively, are the major phosphorylation events
that occur in the lamin A/C N-terminal region. The mono-
phosphorylation of this peptide at Thr-19 was either too
low to be detected by LC-MS/MS or did not occur in mi-
totic HeLa S3 cells. In this scenario, the di-phosphopeptide
SGAQASSTp19PLSp22PTR may represent the major phos-
phoepitope recognized by P-STM in mitotic HeLa S3 cells.
This interpretation is further supported by the observation
that P-STM recognized both the phospho-Thr-19-
containing peptide, SGAQASSTp19PLSPTR, and the
phospho-Thr-19/phospho-Ser-22-containing peptide, SGA
QASSTp19PLSp22PTR, in dot-blot experiments (Figure 3B).
Several lines of evidence suggest that the epitopes recog-
nized by P-STM are not sequence-conserved but may be
structure-related. To date, three phosphoproteins recog-
nized by P-STM have been identified: PAK2 [20], lamin
A/C [21], and MST3 [[32] and Additional file 1: Figure
S5]. Like PAK2, MST3 is also a member of the Ste20 kin-
ase family. An alignment and comparison of the amino
acid sequences of the phosphoepitopes in the three pro-
teins, S398KRSTpMVGTPY (for PAK2), I174KRNTpFVG
TPF (for MST3) and S12GAQASSTpPLSPTR (for lamin
A/C), reveals high homology only between the epitope
sequences from PAK2 and MST3; no obvious similarity
exists between the phosphoepitope from lamin A/C
(S12GAQASSTpPLSPTR) and those from PAK2 or
MST3. The fact that phospho-Thr appears to be the
only conserved ‘structure’ between these three epitope
sequences would seem to suggest that phospho-Thr is
the most critical determinant for generating the P-STM
phosphoepitope. However, we have observed that sev-
eral phosphoproteins containing phospho-Thr, includ-
ing PAK2- and GSK3-phosphorylated MBP, do not react
to P-STM (data not shown). Therefore, the microenvir-
onment surrounding phospho-Thr in a phosphoprotein
may play an important role in creating the epitope rec-
ognized by P-STM. Some additional techniques, includ-
ing three-dimensional structure analysis of the three
phosphoepitopes described above, may be helpful in
analyzing the precise structural requirements for produ-
cing the P-STM phosphoepitope.
Conclusions
The data shown here indicate that P-STM is a valuable
tool for identifying phosphoproteins involved in regulating
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Nocodazole (Noc) was purchased from Sigma (St. Louis,
MO, USA). Anti-lamin A/C antibody (N-18), anti-lamin
antibody conjugated with agarose (636 AC), and sec-
ondary antibodies conjugated with alkaline phosphatase
were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). BCA protein assay reagent was from
Pierce (Rockford, IL, USA). CDK1 was from Upstate
Biotechnology (Lake Placid, NY, USA). Polyvinylidene
fluoride (PVDF) membranes were purchased from Millipore
(Bedford, MA, USA). CDP-Star (a chemiluminescent sub-
strate for alkaline phosphatase) was from Applied Bio-
systems (Bedford, MA, USA). P-STM-11-C peptide
(SKRSTp19MVGTPYC) and peptides A (SGAQASSTp19
PLSp22PTR), B (SGAQASSTp19PLSPTR), C (SGAQAS
STPLSp22PTR), and D (SGAQASSTPLSPTR) were syn-
thesized by Kelowna (Taipei, Taiwan). Sequencing grade
trypsin was from Promega (Madison, WI, USA). Synergi
Polar-RP 4 μm resin was obtained from Phenomenex
(Torrance, CA, USA). Agilent Zorbax 300SB-C18 was
from Agilent Technologies (Santa Clara, CA, USA).
BioBasic C18 300 Å Packed PicoFrit Columns (PFC7515-
BI-10) were from Thermo Fisher Scientific (Waltham,
MA, USA).
P-STM antibody production
The P-STM-11-C peptide (SKRSTp402MVGTPY-C), a
phosphopeptide containing the regulatory autophospho-
rylation site sequence of human PAK2, was coupled to
keyhole limpet hemocyanin and used as an antigen to
produce P-STM antibody in rabbits. Purification and
characterization of this phospho-specific antibody were
as previously described [20].
Cell culture and stable isotope labeling by amino acids in
cell culture (SILAC)
HeLa S3 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% heat-inactivated
fetal bovine serum, 100 units/mL of penicillin/streptomycin
(Invitrogen, Carlsbad, CA, USA) at 37°C in a water-
saturated 5% CO2 atmosphere. The SILAC protocol was
essentially as previously described [33]. Briefly, two
populations of cells were maintained in lysine- and
arginine-depleted DMEM (Biological Industries, Israel)
supplemented with 10% heat-inactivated fetal bovine serum,
100 units/mL of penicillin/streptomycin, and either light
L-lysine (146 mg/L) and L-arginine (84 mg/L) or heavy
[13C6]L-lysine (146 mg/L) and [
13C6]L-arginine (84 mg/L)
(Invitrogen), and additional L-proline (100 mg/L) [34]. Cellswere grown for at least six doublings to allow full incorpor-
ation of labeled amino acids.
Drug treatments and cell extract preparation
Cells were arrested at G2/M phase by incubating for 16 h
with 1 μg/mL nocodazole (Noc), dissolved in dimethyl sulf-
oxide (DMSO). Cells were then were washed twice with
ice-cold phosphate-buffered saline (PBS), and lysed in lysis
buffer (20 mM Tris–HCl pH 7.0, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 1 mM benzamidine, 1 mM
phenylmethylsulfonyl fluoride, 50 mM NaF, 20 mM sodium
pyrophosphate, and 1 mM sodium orthovanadate) on ice
for 15 min. The cell lysates were collected and sonicated on
ice (Model W-380 sonicator; Heat Systems-Ultrasonics
Inc.) (Salem, Massachusetts, USA) for 3 × 10 s at 50%
power, followed by centrifugation at 50,000 × g for 20 min
at 4°C. The supernatant was collected as total cell extract.
Immunoprecipitation
For routine immunoprecipitation, total cell extracts (1 mg
of protein in 0.5 mL of lysis buffer) were incubated with
15 μL of agarose-conjugated anti-lamin A/C antibody
(7.5 μg antibody) at 4°C for 12 h with shaking. Immune
complexes were collected by centrifugation and washed
twice with 0.5 mL of ice-cold solution A (20 mM Tris–HCl
pH 7.0 and 0.5 mM dithiothreitol [DTT]) containing 0.5 M
NaCl and twice with ice-cold solution A without NaCl. For
SILAC experiments, total cell extracts from the two popu-
lations of cells were mixed in a 1:1 ratio and then immu-
noprecipitated as described above.
Construction of plasmids and expression of fusion
proteins
The cDNA sequence for human lamin A/C was retrieved
from the National Center for Biotechnology Information
(NCBI; GeneBank accession number, X03445). Using the
indicated primer pairs and cDNA from A431 cells as a
template, the following lamin regions were amplified by
polymerase chain reaction (PCR): lamin C-N region (aa
1–375), 5′-CGG GAT CCC GAT GGA GAC CCC GTC
CCA G-3′ (forward) and 5′-CGG GAT CCC GGG CGT
GGA TCT CCA TGT CC-3′ (reverse); lamin C-N1 region
(aa 1–57), 5′-CGG GAT CCC GAT GGA GAC CCC
GTC CCA G-3′ (forward) and 5′-CGG AAT TCC TGC
GTT CTC CGT TTC CAG C-3′ (reverse); lamin C-N2
region (aa 58–375), 5′-CGG AAT TCC GGG CTG CGC
CTT CGC ATC-3′ (forward) and 5′-CGG GAT CCC
GGG CGT GGA TCT CCA TGT CC-3′ (reverse); and
lamin C-C region (aa 376–572), 5′-CGG GAT CCC GGT
ACC GCA AGC TCT TGG AGG-3′ (forward) and 5′-
CGG GAT CCC GTC AGC GGC GGC TAC CAC T-3′
(reverse). Expression plasmids for producing GST-fused
fragments of lamin C regions were produced by
digesting PCR products at BamHI/EcoRI restriction
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pGEX-3× bacterial expression vector (GE Healthcare,
Little Chalfont, Buckinghamshire, United Kingdom).
GST-fusion proteins were produced by first transforming
Escherichia coli BL21 with individual plasmids and grow-
ing cells in LB medium containing 100 μg/mL ampicillin.
After cells had reached an optical density at 600 nm
(OD600) of 0.6–0.8, protein expression was induced by
adding isopropyl β-D-1-thiogalactopyranoside (IPTG;
Sigma) to a final concentration of 1 mM and culturing at
30°C for 4 h. Bacteria were harvested by centrifugation
and resuspended in 2 mL of extraction buffer (1 M
Tris–HCl pH 7.4, 2.5 M NaCl, 20% Tween 20, and 1 M
DTT). Cells were lysed by sonicating suspensions (10-s
bursts for 30 min) with a model W-380 sonicator (Heat
Systems-Ultrasonics), and GST-fusion proteins were
purified using glutathione Sepharose beads (Amersham
Biosciences, Sunnyvale, CA, USA).Site-directed mutagenesis
All lamin C mutants were prepared by site-directed muta-
genesis using the QuikChange mutagenesis method
(Stratagene, San Diego, CA, USA) as described by the
manufacturer. The following mutants were generated by
PCR using the indicated primers and the parent plasmid
pGEX-3×-lamin C-N1 (aa 1–57) as a template: Thr-19 to
Ala-19, 5′-CGG GAT CCC GAT GGA GAC CCC GTC
CCA GCG GCG CGC CAC CCG CAG CGG GGC GCA
GGC CAG CTC CGC TCC GCT GTC GCC CAC CCG
C-3′; Ser-22 to Ala-22, 5′-CGG GAT CCC GAT GGA
GAC CCC GTC CCA GCG GCG CGC CAC CCG CAG
CGG GGC GCA GGC CAG CTC CAC TCC GCT GGC
GCC CAC CCG CAT CAC CCG G-3′; and Thr-19/Ser-
22 to Ala-19/Ala-22, 5′-CGG GAT CCC GAT GGA GAC
CCC GTC CCA GCG GCG CGC CAC CCG CAG CGG
GGC GCA GGC CAG CTC CGC TCC GCT GGC GCC
CAC CCG CAT CAC CCG G-3′. PCR products were
digested with the methylation-sensitive restriction endo-
nuclease Dpn1 to eliminate the parent plasmid, and the
reaction products were transformed into DH5α E. coli
(Stratagene). All mutants were confirmed by sequencing.In vitro phosphorylation
Purified GST-lamin C fusion proteins (6 μg each) were
phosphorylated in vitro by incubation in 30 μL of kinase
reaction buffer (20 mM Tris–HCl, 0.5 mM DTT,
20 mM Mg2+ and 0.2 mM ATP or [γ-32P]ATP) containing
60 ng of CDK1 (Upstate Biotechnology) at 30°C for 2 h.
The reaction products were resolved by SDS-PAGE,
followed by autoradiography or Western blot analysis. For
LC-MS/MS analysis, a portion of the reaction product was
reduced (10 mM DTT at 56°C for 1 h), alkylated (30 mM
iodoacetamide at room temperature for 30 min in thedark), and trypsin digested (protein/enzyme mass ratio
50:1 at 37°C for 16 h) in 25 mM NH4HCO3.Immunoblotting
Immunoblotting was carried out essentially as previously
described [20,21]. Affinity-purified P-STM antibody (1 μg/
mL) or commercial anti-lamin A/C antibody (1 μg/mL)
was used to probe proteins transferred from SDS gels to
PVDF membranes. The proteins of interest were detected
using goat anti-rabbit IgG antibody conjugated with alka-
line phosphatase and the alkaline phosphatase substrate
CDP-Star according to the procedure provided by the
manufacturer. For reprobing, membranes were stripped
with 2% SDS, 100 mM 2-mercaptoethanol and 62.5 mM
Tris at 56°C for 45 min with occasional agitation, washed
three times in TTBS buffer (20 mM Tris–HCl at pH 7.4,
0.5 M NaCl and 0.05% [v/v] Tween 20), and then reprobed
with another antibody.In-gel digestion of proteins and mass spectrometric
analysis
Coomassie Blue-stained protein bands were excised
from the gel and in-gel digested with trypsin according
to a protocol described previously [35]. Briefly, the ex-
cised protein bands were washed twice with 50% aceto-
nitrile containing 25 mM NH4HCO3 for 15 min and
then with acetonitrile several times. After drying, the
gel pieces were subjected to reduction and alkylation by
DTT/iodoacetamide in 25 mM NH4HCO3, followed by
in-gel digestion with freshly prepared enzyme solution
(20 ng/μL of trypsin in 25 mM NH4HCO3) at 37°C for
16 h. The resulting tryptic peptides were reconstituted
in HPLC (high-performance liquid chromatography)
buffer A (0.05% formic acid; Sigma) and then analyzed
by LC-MS/MS. LC-MS/MS data were acquired on a
nanoLC U3000 system (Dionex, Sunnyvale, CA, USA)
equipped with micrOTOFq (Bruker Daltonik GmbH,
Bremen, Germany) and operated using micrOTOF con-
trol software. Samples were loaded onto a trap column
(Zorbax 300SB-C18, 0.3 × 5 mm; Agilent Technologies,
Wilmington, DE, USA) at a flow rate of 5 μL/min in
HPLC buffer A. After reducing the flow rate to 25 nL/min
using a splitter, peptides were separated on an analytical
column (Synergy Hydro-RP capillary RP18 column,
2.5 μm, 0.15 × 100 mm; packed in house) using a gradient
of 5% to 80% HPLC buffer B (0.05% formic acid in 100%
acetonitrile) in 75 min. Peptide fragment spectra were ac-
quired from one MS scan, followed by four MS/MS scans
of the most abundant parent ions. Each precursor was an-
alyzed twice and then excluded in the following minute.
MS data were processed with DataAnalysis v.3.4 (Bruker
Daltonics) to generate peak lists and .mgf files (Mascot
generic format files) for database searches.
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56.1 FASTA Database (Homo sapiens, 15720 sequences),
assuming trypsin as the digesting enzyme. The MASCOT
search engine (http://www.matrixscience.com) (v.2.2.03
Matrix Science, London, UK) was used with the following
parameters: one missing cleavage site allowed with charge
states from 1+ to 3+; MS mass tolerance set to 50 ppm
and MS/MS tolerance set to 0.1 Da for both fixed modifi-
cation (carbamidomethylation of Cys) and variable modifi-
cations (oxidation of Met, phosphorylation of Ser/Thr,
and 13C6-incorporation of Lys/Arg for SILAC labeling).Peptide quantification
Peptide pairs from SILAC samples were quantified as fol-
lows. First, peptides with an ion score >15 were identified
from the exported MASCOT search results (*.xtmL) using
BioTools software (Bruker Daltonics). The search results of
each identified phosphopeptide were further checked and
verified by manual alignment. Second, the light and heavy
peptide pairs were identified using DataAnalysis software
(Bruker Daltonics). The retention time (RT) and mass of a
light peptide detected in an LC-run were used as bases to
set a time window (RT ± 15 s) and a mass window [(mass +
6.02/12.04 Da) ± 0.05 Da)] to find its coeluted, paired
heavy peptide. Third, the area of extracted ion chromato-
gram (EIC) of each light or heavy peptide was obtained
and used to calculate the EIC ratio (heavy/light) of each
peptide pair using WARP-LC software (Bruker Daltonics).
Fourth, for a specific peptide pair with multiple EIC ratios
(because of repeated detection in a single LC-run), the
mean EIC ratio was calculated and used as the average
EIC ratio of each peptide pair detected/quantified in an
LC-run. Finally, the quantified results [Noc/Ctrl ratios
obtained from EIC ratios (heavy/light)] of each peptide
pair from the four LC-runs were averaged to obtain the
final average Noc/Ctrl ratio of each peptide pair.Additional files
Additional file 1: Figure S1. Assignments of MS/MS spectra of the four
synthetic peptides. Figure S2. Assignments of MS/MS spectra of the four
tryptic peptides obtained from the in vitro-phosphorylated sample.
Figure S3. Sequence coverage of lamin A immunoprecipitated from
Noc-treated HeLa S3 cells, as assessed by LC-MS/MS. Figure S4.
Sequence coverage of lamin C immunoprecipitated from Noc-treated
HeLa S3 cells, as assessed by LC-MS/MS. Figure S5. Phosphorylation of
the regulatory autophosphorylation site Thr-178 of MST3 creates a
recognition motif for the P-STM antibody.
Additional file 2: Table S1. SILAC-based quantification of tryptic
peptides of lamins A and C immunoprecipitated from HeLa S3 cells.Abbreviations
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